Jihwan Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jihwan Yun has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Hee Jin Kim
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5 shared publications - Hyemin Jang
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
5 shared publications - Duk Lyul Na
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4 shared publications - Henrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
4 shared publications - Jun Pyo Kim
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4 shared publications - Kaj Blennow
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
4 shared publications
Latest Publications
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213954
Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease
Identifying β-amyloid (Aβ) positivity is crucial for selecting candidates for Aβ-targeted therapies in early-stage Alzheimer disease (AD). While Aβ PET is accurate, its high cost limits routine use. Plasma p-tau217 testing offers a less invasive option but also incurs additional costs. Structural brain MRI, routinely used in cognitive assessments, can identify features predictive of Aβ positivity without extra expense. We evaluated a 2-stage workflow integrating MRI-based features and plasma p-tau217 to efficiently predict Aβ PET positivity in early-stage AD. This prospective cohort study included participants with mild cognitive impairment (MCI) or early Alzheimer-type dementia (ATD) from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD; Korea) and Alzheimer's Disease Neuroimaging Initiative (ADNI; US) cohorts. Eligible participants had a Clinical Dementia Rating score of 0.5, along with MRI, plasma p-tau217, and Aβ PET data. A random forest classifier predicting Aβ PET positivity was developed using MRI-based brain atrophy patterns and APOE ε4 status. Participants were stratified into low-risk, intermediate-risk, and high-risk groups; plasma p-tau217 testing was performed only in intermediate-risk individuals. Outcomes included positive predictive value (PPV), negative predictive value (NPV), and overall accuracy. A total of 807 K-ROAD participants (median age 72.0 years, 58.7% female) and 230 ADNI participants (median age 70.9 years, 49.1% female) were analyzed. Using a 95% sensitivity/specificity strategy, the low-risk group demonstrated NPVs of 94.7% (91.7%-97.7%, K-ROAD) and 99.0% (97.0%-100.0%, ADNI). The high-risk group showed PPVs of 97.6% (95.9%-99.3%, K-ROAD) and 98.8% (96.5%-100.0%, ADNI). Intermediate-risk groups comprised 33.3% (K-ROAD) and 20.9% (ADNI) of participants. Plasma p-tau217 testing in intermediate-risk groups yielded PPVs of 92.5% (88.7%-96.3%, K-ROAD) and 90.0% (79.0%-100.0%, ADNI) and NPVs of 83.1% (75.0%-91.2%, K-ROAD) and 83.3% (66.1%-100.0%, ADNI). The overall workflow accuracy was 94.2% (92.6%-95.8%, K-ROAD) and 96.5% (94.1%-98.9%, ADNI). The 2-stage diagnostic workflow integrating MRI-based risk stratification and plasma p-tau217 testing accurately identified individuals with Aβ PET positivity in early-stage AD, substantially reducing the need for additional biomarker testing. However, the generalizability may be limited by modest incremental improvement over baseline models and limited racial and ethnic diversity.
- 23 September 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (6) , e213954
Open AccessIntegrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease
Identifying β-amyloid (Aβ) positivity is crucial for selecting candidates for Aβ-targeted therapies in early-stage Alzheimer disease (AD). While Aβ PET is accurate, its high cost limits routine use. Plasma p-tau217 testing offers a less invasive option but also incurs additional costs. Structural brain MRI, routinely used in cognitive assessments, can identify features predictive of Aβ positivity without extra expense. We evaluated a 2-stage workflow integrating MRI-based features and plasma p-tau217 to efficiently predict Aβ PET positivity in early-stage AD. This prospective cohort study included participants with mild cognitive impairment (MCI) or early Alzheimer-type dementia (ATD) from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD; Korea) and Alzheimer's Disease Neuroimaging Initiative (ADNI; US) cohorts. Eligible participants had a Clinical Dementia Rating score of 0.5, along with MRI, plasma p-tau217, and Aβ PET data. A random forest classifier predicting Aβ PET positivity was developed using MRI-based brain atrophy patterns and APOE ε4 status. Participants were stratified into low-risk, intermediate-risk, and high-risk groups; plasma p-tau217 testing was performed only in intermediate-risk individuals. Outcomes included positive predictive value (PPV), negative predictive value (NPV), and overall accuracy. A total of 807 K-ROAD participants (median age 72.0 years, 58.7% female) and 230 ADNI participants (median age 70.9 years, 49.1% female) were analyzed. Using a 95% sensitivity/specificity strategy, the low-risk group demonstrated NPVs of 94.7% (91.7%-97.7%, K-ROAD) and 99.0% (97.0%-100.0%, ADNI). The high-risk group showed PPVs of 97.6% (95.9%-99.3%, K-ROAD) and 98.8% (96.5%-100.0%, ADNI). Intermediate-risk groups comprised 33.3% (K-ROAD) and 20.9% (ADNI) of participants. Plasma p-tau217 testing in intermediate-risk groups yielded PPVs of 92.5% (88.7%-96.3%, K-ROAD) and 90.0% (79.0%-100.0%, ADNI) and NPVs of 83.1% (75.0%-91.2%, K-ROAD) and 83.3% (66.1%-100.0%, ADNI). The overall workflow accuracy was 94.2% (92.6%-95.8%, K-ROAD) and 96.5% (94.1%-98.9%, ADNI). The 2-stage diagnostic workflow integrating MRI-based risk stratification and plasma p-tau217 testing accurately identified individuals with Aβ PET positivity in early-stage AD, substantially reducing the need for additional biomarker testing. However, the generalizability may be limited by modest incremental improvement over baseline models and limited racial and ethnic diversity.
- Open Access
- 1 September 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (12) , 1120-1129
Prognostic Value of A/T/N Biomarkers
Background: Alzheimer disease (AD) is characterized by amyloid-β plaques (A), tau tangles (T), and neurodegeneration (N), collectively defining the ATN framework. While imaging biomarkers are well-established, the prognostic value of plasma biomarkers in predicting cognitive decline remains underexplored. This study compares plasma and imaging A/T/N biomarkers in predicting cognitive decline and evaluate the impact of combining biomarkers across modalities. Patients and Methods: We conducted a longitudinal study using K-ROAD cohort participants who underwent at least 2 cognitive assessments. All participants had plasma biomarker testing (Aβ ratio, p-tau181, p-tau231, p-tau217, NfL), and a subset with imaging biomarker assessments (Aβ PET, tau PET, structural MRI) formed an imaging subcohort. Multiple linear regression models identified the most predictive markers within each modality and evaluated the effect of combining A/T/N biomarkers. Results: Among 1,614 plasma cohort and 130 imaging subcohort participants, tau markers demonstrated the strongest predictive value. p-tau217 MSD outperforming other plasma biomarkers, and the neo-temporal ROI showing the highest predictive power among imaging biomarkers. In plasma-based model, adding neurodegeneration markers to combination of amyloid and tau biomarkers improved the performance. In imaging-based models, same strategy decreased the performance, suggesting that combinations of amyloid and tau PET captures the most relevant prognostic information. Conclusions: Imaging biomarkers, particularly tau PET, show superior prognostic accuracy compared with plasma biomarkers, whereas plasma biomarkers offer advantages in combination models through neurodegeneration markers. These findings underscore the complementary roles of plasma and imaging biomarkers and emphasize the need for tailored strategies for prognostic modeling in AD.
- 1 September 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (12) , 1120-1129
Open AccessPrognostic Value of A/T/N Biomarkers
Background: Alzheimer disease (AD) is characterized by amyloid-β plaques (A), tau tangles (T), and neurodegeneration (N), collectively defining the ATN framework. While imaging biomarkers are well-established, the prognostic value of plasma biomarkers in predicting cognitive decline remains underexplored. This study compares plasma and imaging A/T/N biomarkers in predicting cognitive decline and evaluate the impact of combining biomarkers across modalities. Patients and Methods: We conducted a longitudinal study using K-ROAD cohort participants who underwent at least 2 cognitive assessments. All participants had plasma biomarker testing (Aβ ratio, p-tau181, p-tau231, p-tau217, NfL), and a subset with imaging biomarker assessments (Aβ PET, tau PET, structural MRI) formed an imaging subcohort. Multiple linear regression models identified the most predictive markers within each modality and evaluated the effect of combining A/T/N biomarkers. Results: Among 1,614 plasma cohort and 130 imaging subcohort participants, tau markers demonstrated the strongest predictive value. p-tau217 MSD outperforming other plasma biomarkers, and the neo-temporal ROI showing the highest predictive power among imaging biomarkers. In plasma-based model, adding neurodegeneration markers to combination of amyloid and tau biomarkers improved the performance. In imaging-based models, same strategy decreased the performance, suggesting that combinations of amyloid and tau PET captures the most relevant prognostic information. Conclusions: Imaging biomarkers, particularly tau PET, show superior prognostic accuracy compared with plasma biomarkers, whereas plasma biomarkers offer advantages in combination models through neurodegeneration markers. These findings underscore the complementary roles of plasma and imaging biomarkers and emphasize the need for tailored strategies for prognostic modeling in AD.
- Open Access
- 22 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70352
Integrating visual assessments and quantification methods for tau PET staging
INTRODUCTION: We compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.METHODS: Tau PET scans from 289 Korea‐Registries to Overcome Dementia and Accelerate Dementia Research (K‐ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.RESULTS: FreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta‐region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T− to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K‐ROAD and ADNI cohorts.DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories.Highlights: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta‐temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea‐Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.
- 22 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70352
Open AccessIntegrating visual assessments and quantification methods for tau PET staging
INTRODUCTION: We compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.METHODS: Tau PET scans from 289 Korea‐Registries to Overcome Dementia and Accelerate Dementia Research (K‐ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.RESULTS: FreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta‐region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T− to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K‐ROAD and ADNI cohorts.DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories.Highlights: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta‐temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea‐Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.
- Open Access
- 1 January 2025
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 24 (2) , 91-101
Reproducibility of Plasma Biomarker Measurements Across Laboratories: Insights Into ptau217, GFAP, and NfL
Kang H, et al. Dement Neurocogn Disord. 2025 Apr;24(2):91-101. https://doi.org/10.12779/dnd.2025.24.2.91
- 1 January 2025
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 24 (2) , 91-101
Open AccessReproducibility of Plasma Biomarker Measurements Across Laboratories: Insights Into ptau217, GFAP, and NfL
Kang H, et al. Dement Neurocogn Disord. 2025 Apr;24(2):91-101. https://doi.org/10.12779/dnd.2025.24.2.91
- Open Access
- 14 September 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (12) , e16482
Difference in trajectories according to early amyloid accumulation in cognitively unimpaired elderly
Background and purpose: Amyloid β (Aβ), a major biomarker of Alzheimer's disease, leads to tau accumulation, neurodegeneration and cognitive decline. Modelling the trajectory of Aβ accumulation in cognitively unimpaired (CU) individuals is crucial, as treatments targeting Aβ are anticipated. The evolution of Aβ levels was investigated to determine whether it could lead to classification into different groups by studying longitudinal Aβ changes in older CU individuals, and differences between the groups were compared.Methods: A total of 297 CU participants were included from the Alzheimer's Disease Neuroimaging Initiative database, and these participants underwent apolipoprotein E (APOE) genotyping, neuropsychological testing, brain magnetic resonance imaging, and an average of 3.03 follow‐up 18F‐florbetapir positron emission tomography scans. Distinct Aβ trajectory patterns were classified using latent class growth analysis, and longitudinal cognitive performances across these patterns were assessed with a linear mixed effects model.Results: The optimal model consisted of three classes, with a high entropy value of 0.947. The classes were designated as follows: class 1, non‐accumulation group (n = 197); class 2, late accumulation group (n = 70); and class 3, early accumulation group (n = 30). The late accumulation and early accumulation groups had more APOE ε4 carriers than the non‐accumulation group. The longitudinal analysis of cognitive performance revealed that the early accumulation group showed the steepest decline (modified Preclinical Alzheimer's Cognitive Composite with digit symbol substitution [mPACCdigit], p < 0.001; modified Preclinical Alzheimer's Cognitive Composite with trails B [mPACCtrailsB], p < 0.001) and the late accumulation group showed a steeper decline (mPACCdigit, p = 0.014; mPACCtrailsB, p = 0.007) compared to the non‐accumulation group.Conclusions: Our study showed the heterogeneity of Aβ accumulation trajectories in CU older individuals. The prognoses for cognitive decline differ according to the Aβ trajectory patterns.
- 14 September 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (12) , e16482
Open AccessDifference in trajectories according to early amyloid accumulation in cognitively unimpaired elderly
Background and purpose: Amyloid β (Aβ), a major biomarker of Alzheimer's disease, leads to tau accumulation, neurodegeneration and cognitive decline. Modelling the trajectory of Aβ accumulation in cognitively unimpaired (CU) individuals is crucial, as treatments targeting Aβ are anticipated. The evolution of Aβ levels was investigated to determine whether it could lead to classification into different groups by studying longitudinal Aβ changes in older CU individuals, and differences between the groups were compared.Methods: A total of 297 CU participants were included from the Alzheimer's Disease Neuroimaging Initiative database, and these participants underwent apolipoprotein E (APOE) genotyping, neuropsychological testing, brain magnetic resonance imaging, and an average of 3.03 follow‐up 18F‐florbetapir positron emission tomography scans. Distinct Aβ trajectory patterns were classified using latent class growth analysis, and longitudinal cognitive performances across these patterns were assessed with a linear mixed effects model.Results: The optimal model consisted of three classes, with a high entropy value of 0.947. The classes were designated as follows: class 1, non‐accumulation group (n = 197); class 2, late accumulation group (n = 70); and class 3, early accumulation group (n = 30). The late accumulation and early accumulation groups had more APOE ε4 carriers than the non‐accumulation group. The longitudinal analysis of cognitive performance revealed that the early accumulation group showed the steepest decline (modified Preclinical Alzheimer's Cognitive Composite with digit symbol substitution [mPACCdigit], p < 0.001; modified Preclinical Alzheimer's Cognitive Composite with trails B [mPACCtrailsB], p < 0.001) and the late accumulation group showed a steeper decline (mPACCdigit, p = 0.014; mPACCtrailsB, p = 0.007) compared to the non‐accumulation group.Conclusions: Our study showed the heterogeneity of Aβ accumulation trajectories in CU older individuals. The prognoses for cognitive decline differ according to the Aβ trajectory patterns.
- Open Access
- 31 December 2019
- Published by Korean Society of Neurosonology in Journal of Neurosonology and Neuroimaging
- Vol. 11 (2) , 145-148
Movable Thrombi Diagnosed Using Ultrasonography in Non-Significant Carotid Stenosis
- 31 December 2019
- Published by Korean Society of Neurosonology in Journal of Neurosonology and Neuroimaging
- Vol. 11 (2) , 145-148
Open AccessMovable Thrombi Diagnosed Using Ultrasonography in Non-Significant Carotid Stenosis